ATE309250T1 - Modulatoren der protein tyrosin phosphatase (ptpases) - Google Patents

Modulatoren der protein tyrosin phosphatase (ptpases)

Info

Publication number: ATE309250T1
Authority: AT; Austria
Prior art keywords: sub; ptpases; protein tyrosine; modulators; compounds
Prior art date: 1999-09-10

Application number

AT00958277T

Other languages

English (en)

Inventor

Henrik Sune Andersen

Thomas Kruse Hansen

Jesper Lau

Yu Ge

Daniel Dale Holsworth

Todd Kevin Jones

Luke Milburn Judge

Wiliam Charles Ripka

Barry Zvi Shapira

Roy Teruyuki Uyeda

Original Assignee

Novo Nordisk As

Ontogen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-10

Filing date

2000-09-11

Publication date

2005-11-15

2000-09-11 Application filed by Novo Nordisk As, Ontogen Corp filed Critical Novo Nordisk As

2005-11-15 Application granted granted Critical

2005-11-15 Publication of ATE309250T1 publication Critical patent/ATE309250T1/de

Links

102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title abstract 3
108020000494 protein-tyrosine phosphatase Proteins 0.000 title abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
208000002705 Glucose Intolerance Diseases 0.000 abstract 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 abstract 1
101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
206010022489 Insulin Resistance Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
-1 PTPalpha Proteins 0.000 abstract 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 abstract 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 abstract 1
101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
201000009104 prediabetes syndrome Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pulmonology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Electrodes Of Semiconductors (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Enzymes And Modification Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT00958277T 1999-09-10 2000-09-11 Modulatoren der protein tyrosin phosphatase (ptpases) ATE309250T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA199901278		1999-09-10
PCT/DK2000/000503 WO2001019831A1 (en)	1999-09-10	2000-09-11	MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)

Publications (1)

Publication Number	Publication Date
ATE309250T1 true ATE309250T1 (de)	2005-11-15

Family

ID=8103050

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00958277T ATE309250T1 (de)	1999-09-10	2000-09-11	Modulatoren der protein tyrosin phosphatase (ptpases)

Country Status (7)

Country	Link
US (1)	US7019026B1 (de)
EP (1)	EP1214325B1 (de)
JP (1)	JP2003509430A (de)
AT (1)	ATE309250T1 (de)
AU (1)	AU6985300A (de)
DE (1)	DE60023923D1 (de)
WO (1)	WO2001019831A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001017516A2 (en) *	1999-09-10	2001-03-15	Novo Nordisk A/S	Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
HUP0303172A3 (en) *	2000-06-28	2006-05-29	Bristol Myers Squibb Co	Selective androgen receptor modulators and methods for their identification, desing and use
US7001911B2 (en)	2000-06-28	2006-02-21	Bristol-Myers Squibb Company	Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en)	2001-06-20	2004-04-22	Salvati Mark E.	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6613903B2 (en)	2000-07-07	2003-09-02	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (PTPases)
WO2002004459A1 (en) *	2000-07-07	2002-01-17	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
US6972340B2 (en)	2000-08-29	2005-12-06	Abbott Laboratories	Selective protein tyrosine phosphatatase inhibitors
IL155019A0 (en) *	2000-09-19	2003-10-31	Bristol Myers Squibb Co	Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en)	2000-09-19	2005-10-11	Bristol-Myers Squibb Company	Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
WO2002100397A1 (en) *	2001-06-07	2002-12-19	Wyeth	COMBINATION OF A PTPase INHIBITOR AND AN ANTILIPEMIC AGENT
US7291639B2 (en) *	2001-06-20	2007-11-06	Wyeth	Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7087636B2 (en)	2001-12-19	2006-08-08	Bristol-Myers Squibb Company	Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2007229370B2 (en) *	2002-04-03	2010-06-17	Novartis Ag	5-substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as PTPase 1B inhibitors
ATE534637T1 (de)	2002-04-03	2011-12-15	Novartis Ag	5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer
US7169797B2 (en)	2003-02-14	2007-01-30	Abbott Laboratories	Protein-tyrosine phosphatase inhibitors and uses thereof
EP1670804A2 (de) *	2003-09-10	2006-06-21	GPC Biotech AG	Heterobicyclische verbindungen als pharmazeutisch wirksame mittel
WO2005035551A2 (en)	2003-10-08	2005-04-21	Incyte Corporation	Inhibitors of proteins that bind phosphorylated molecules
WO2005081954A2 (en)	2004-02-25	2005-09-09	Wyeth	Inhibitors of protein tyrosine phosphatase 1b
SE0500055D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
JP2008536925A (ja) *	2005-04-20	2008-09-11	メルクエンドカムパニーインコーポレーテッド	ベンゾチオフェンヒドロキサム酸誘導体
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2985271A1 (en)	2007-09-06	2009-03-12	Ohr Pharmaceutical, Inc.	A method for treating diabetes
DK2308877T3 (da)	2008-08-05	2014-04-22	Daiichi Sankyo Co Ltd	Imidazopyridin-2-on-derivater
CN104193761B (zh)	2009-12-04	2017-10-17	桑诺维恩药品公司	多环化合物及其使用方法
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru)	2010-04-22	2015-11-27	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения циклоалкилкарбоксамидо-индольных соединений
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
EP2683698B1 (de)	2011-03-08	2017-10-04	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102199157B (zh) *	2011-03-17	2013-04-17	鲁东大学	一种含溴的苯并吡喃类化合物及其制备和应用
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20150003798A (ko)	2012-04-20	2015-01-09	오에이치알 파마서티컬, 인코포레이티드	Ptp1b 연관 질병의 치료용 아미노스테로이드
PL3925607T5 (pl)	2014-04-15	2026-06-01	Vertex Pharmaceuticals Incorporated	Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
JP6389531B2 (ja) *	2014-04-28	2018-09-12	ジアンスカニョンファーマシューティカルカンパニーリミテッド	抗エンテロウイルス７１チアジアゾリジン誘導体
CN107325075B (zh) *	2016-04-29	2020-07-28	正大天晴药业集团股份有限公司	一种泊马度胺的制备方法
SG10202100724UA (en)	2016-07-29	2021-03-30	Sunovion Pharmaceuticals Inc	Compounds and compositions and uses thereof
BR112019001407A2 (pt)	2016-07-29	2019-07-09	Sunovion Pharmaceuticals Inc.	compostos e composições e usos dos mesmos
EP3582815A1 (de)	2017-02-16	2019-12-25	Sunovion Pharmaceuticals Inc.	Verfahren zur behandlung von schizophrenie
MX2020000523A (es)	2017-08-02	2020-08-20	Sunovion Pharmaceuticals Inc	Compuestos de isocromano y usos de los mismos.
SG11202007823PA (en)	2018-02-16	2020-09-29	Sunovion Pharmaceuticals Inc	Salts, crystal forms, and production methods thereof
JP7703449B2 (ja)	2019-03-14	2025-07-07	スミトモ・ファーマ・アメリカ・インコーポレイテッド	イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
CN110054993B (zh) *	2019-04-04	2021-02-26	筑迹(深圳)创新健康科技有限公司	一种长寿命有机硅聚合物抗菌液及其制备方法、抗菌涂层的制备方法
KR20230003503A (ko)	2020-04-14	2023-01-06	선오비온 파마슈티컬스 인코포레이티드	신경학적 및 정신의학적 장애의 치료를 위한 (S)-(4,5-디히드로-7H-티에노[2,3-c]피란-7-일)-N-메틸메탄아민

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3953468A (en)	1974-03-15	1976-04-27	The Upjohn Company	3-Cyano thiophen-2-yl oxamic acid and derivatives
GB1583679A (en)	1977-10-11	1981-01-28	Bristol Myers Co	Thieno (2,3-d) pyrimidine and other thiophene-derived anti-allergic agents
WO1999046267A1 (en) *	1998-03-12	1999-09-16	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) *	1998-03-12	2001-07-17	Novo Nordisk A/S	Modulators of protein tyrosine phosphatases (PTPASES)
JP2002506073A (ja) *	1998-03-12	2002-02-26	ノボノルディスクアクティーゼルスカブ	プロテイン・チロシン・ホスファターゼ（ＰＴＰａｓｅｓ）のモジュレーター
JP2004500308A (ja) *	1998-03-12	2004-01-08	ノボ　ノルディスク　アクティーゼルスカブ	プロテインチロシンホスアターゼのモジュレーター

2000
- 2000-09-11 EP EP00958277A patent/EP1214325B1/de not_active Expired - Lifetime
- 2000-09-11 JP JP2001523408A patent/JP2003509430A/ja active Pending
- 2000-09-11 US US09/662,457 patent/US7019026B1/en not_active Expired - Fee Related
- 2000-09-11 DE DE60023923T patent/DE60023923D1/de not_active Expired - Lifetime
- 2000-09-11 WO PCT/DK2000/000503 patent/WO2001019831A1/en not_active Ceased
- 2000-09-11 AU AU69853/00A patent/AU6985300A/en not_active Abandoned
- 2000-09-11 AT AT00958277T patent/ATE309250T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2001019831A1 (en)	2001-03-22
JP2003509430A (ja)	2003-03-11
EP1214325B1 (de)	2005-11-09
US7019026B1 (en)	2006-03-28
DE60023923D1 (de)	2005-12-15
EP1214325A1 (de)	2002-06-19
AU6985300A (en)	2001-04-17

Legal Events

Date	Code	Title	Description
2006-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60023923D1 (de)	2005-12-15	Modulatoren der protein tyrosin phosphatase (ptpases)
ATE329920T1 (de)	2006-07-15	Modulatoren der protein tyrosin phosphatase (ptpases)
ATE321052T1 (de)	2006-04-15	Modulatoren von protein tyrosin phosphatasen (ptpasen)
DE69910045D1 (de)	2003-09-04	Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
BR0109062A (pt)	2002-11-26	Inibidores de frutose-1,6-bisfosfatase de arila
ATE396993T1 (de)	2008-06-15	Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
NO20043259L (no)	2004-09-16	Bindingsproteiner som biosensorer
EP1644514A4 (de)	2009-05-27	Temperaturstabile amylase-polypeptide, für diese polypeptide codierende nukleinsäuren und verwendungen davon
PT914299E (pt)	2002-12-31	Composicoes de vidro silico-sodo-calcicas e suas aplicacoes
ATE465748T1 (de)	2010-05-15	Vernetzte, nicht von pilzen kommende lipase enthaltende zusammensetzung und methoden zu deren verwendung
DK0833839T3 (da)	2003-04-14	Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
DK1070056T3 (da)	2004-11-08	Phthalazinon-PDE III/IV-inhibitorer
AU8023898A (en)	1998-12-30	Combined product associating a nucleic acid with a substance breaking up the extracellular matrix for gene therapy
BR0213015A (pt)	2004-10-05	ElastÈmeros termoplásticos de poliuretano-silicone
EP2314689A3 (de)	2012-12-19	Antisense-Verbindungen, die gegen Connexine gerichtet sind, und Verfahren zu deren Verwendung
ATE355284T1 (de)	2006-03-15	Inhibitoren von serinproteasen
PT1149092E (pt)	2004-03-31	4- e 5-alciniloxindois e 4- e 5-alceniloxindois
EP0948327A4 (de)	2003-04-02	Antidiabetische mittel
PT1267869E (pt)	2004-10-29	Antogonistas de receptor de glutamato metabotropico para o tratamento de tolerancia e de dependencia
ATE269340T1 (de)	2004-07-15	Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
WO2004063185A8 (en)	2004-09-23	Thiophene carboxamides as inhibitors of the enzyme ikk-2
SE9903290D0 (sv)	1999-09-15	Novel compounds
DK1377574T3 (da)	2005-04-25	6-phenylbenzonaphtyridiner
ATE298244T1 (de)	2005-07-15	Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ATE218138T1 (de)	2002-06-15	N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung